Vimelea Therapeutics is a pre-clinical stage drug development company. We are developing a novel platform of therapeutic small molecules that treat various inflammatory diseases. Our new class of chemical compounds were designed from an immunomodulating system in nature. Our library of small molecules provides numerous development opportunities for our therapeutic target, cutaneous lupus erythematosus (CLE), as well as a significant number of other autoimmune and chronic inflammatory disease.
Vimelea’s lead compounds modulate both myeloid and lymphoid immune cells. Both cell types play a role in CLE pathology. Our compounds are only active in unbalanced immune tissue, thus mitigating toxicity in healthy tissue. The compounds’ size and chemical structures also make for efficient manufacturing.
Dr. Darius M. Walker
Dr. Aubrey Watkins III
Mr. Steven M. Walker, MBA, MHA
Dr. Christine Copple
Mr. Brad Stewart
Mr. Jarrod Longcor, MBA, MPH, MSMS
Prof. William Harnett
Prof. Colin Suckling
9711 Washingtonian Boulevard, Suite 550 Gaithersburg, Maryland 20878, United States